- Roth Capital initiated coverage of Unicycive Therapeutics UNCY with a Buy rating and $13.50 price target.
- Analyst Elemer Piros says that the Company could submit a marketing application to the FDA for Renasorb to treat hyperphosphatemia in chronic kidney disease, or CKD, in "about a year."
- The analyst also believes that Renasorb has the potential to become "a dominant player in the kidney disease market."
- Unicycive started trading on NASDAQ in July. It offered 5 million units at $5/unit.
- Price Action: UNCY shares closed up 14% at $3.05 on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorBiotechLong IdeasNewsPenny StocksHealth CareInitiationIPOsAnalyst RatingsMoversTrading IdeasGeneralBriefsChronic Kidney Disease
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in